Isabella Raccagni

Isabella Raccagni
Università degli Studi di Milano-Bicocca | UNIMIB · Department of Health Science

About

19
Publications
1,892
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
199
Citations
Additional affiliations
February 2017 - present
Italian National Research Council
Position
  • Fellow
February 2016 - January 2017
Tecnomed Foundation of the University of Milan Bicocca
Position
  • Fellow
February 2015 - January 2016
Università degli Studi di Milano-Bicocca
Position
  • PostDoc Position
Education
December 2012 - February 2015
Università degli Studi di Milano-Bicocca
Field of study
  • Biomedical Technology

Publications

Publications (19)
Conference Paper
Full-text available
Introduction Cancer aberrant N- and O-linked protein glycosylation, frequently resulting from an augmented flux through the Hexosamine Biosynthetic Pathway (HBP), play different roles in tumour progression. Recent studies reported an association between the tumorigenic potential, metastasis and chemoresistance of several type of breast cancer cells...
Article
Full-text available
Rationale Pathological response to neo-adjuvant chemotherapy (NAC) represents a commonly used predictor of survival in triple negative breast cancer (TNBC) and the need to identify markers that predict response to NAC is constantly increasing. Aim of this study was to evaluate the potential usefulness of PET imaging with [¹⁸F]FDG and [¹⁸F]FLT for t...
Data
[18F]FDG and [18F]FLT SUVmax. [18F]FDG and [18F]FLT SUVmax calculated at the baseline (pre) and post treatment (post) in vehicle and treated mice categorized on the basis of TVR. Multiple comparison assessed using 2-way ANOVA analysis and *p < 0.05, **p < 0.01 and ***p < 0.001. (TIF)
Data
Variation of [18F]FDG and [18F]FLT uptake. [18F]FDG and [18F]FLT uptake expressed as percent variation (% change) in A) TLG (Total Lesion Glycolysis) or TLP (Total lesion Proliferation) and B) MTV (Metabolic Tumor Volume) between baseline and post-therapy in vehicle and treated mice categorized on the basis of TVR. (TIF)
Data
ARRIVE guidelines checklist. (DOCX)
Article
Full-text available
Cancer aberrant N- and O-linked protein glycosylation, frequently resulting from an augmented flux through the Hexosamine Biosynthetic Pathway (HBP), play different roles in tumor progression. However, the low specificity and toxicity of the existing HBP inhibitors prevented their use for cancer treatment. Here we report the preclinical evaluation...
Article
Full-text available
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor survival. Cytoreduction in association with radiotherapy and temozolomide (TMZ) is the standard therapy, but response is heterogeneous and life expectancy is limited. The combined use of chemotherapeutic agents with drugs targeting cell metabolism is becoming an inte...
Article
PurposeIn tumour, the imbalance between oxygen supply and demand leads to hypoxia, which represents a negative prognostic factor associated with aggressive tumour phenotype and therapy resistance. This review provides an overview of the use of positron emitter-labelled radiopharmaceutical used to image hypoxia in preclinical models of cancer. Metho...
Article
Purpose: Lung cancer heterogeneity makes response to therapy extremely hard to predict. Patient-derived xenografts (PDXs) represent a reliable preclinical model that closely recapitulates the main characteristics of the primary tumor and could represent a useful asset to test new therapies. Here, using PET imaging, we verify how lung cancer PDXs r...
Article
The factors that determine whether disseminated transformed cells in vivo yield neoplastic lesions have only been partially identified. We established an ad hoc model of peritoneal carcinomatosis by injecting colon carcinoma cells in mice. Tumor cells recruit inflammatory leukocytes, mostly macrophages, and generate neoplastic peritoneal lesions. P...
Article
Full-text available
The 18-kDa mitochondrial translocator protein (TSPO) is known to be highly expressed in several types of cancer, including gliomas, whereas expression in normal brain is low. TSPO functions in glioma are still incompletely understood. The TSPO can be quantified pre-operatively with molecular imaging making it an ideal candidate for personalized tre...
Article
Full-text available
Hypoxia-inducible factor 1α (HIF-1α) activity is one of the major players in hypoxia-mediated glioma progression and resistance to therapies, and therefore the focus of this study was the evaluation of HIF-1α modulation in relation to tumour response with the purpose of identifying imaging biomarkers able to document tumour response to treatment in...
Article
The aim of this study was to characterize a cell-based model for the molecular study of hypoxia-inducible factor (HIF)-1α activity, in the context of hypoxia, by means of different imaging techniques. Engineered U251-HRE glioma cells were used to analyze the molecular mechanisms underlying HIF-1α activity in vitro in relation to luciferase expressi...
Article
The prognosis of malignant gliomas remains largely unsatisfactory for the intrinsic characteristics of the pathology and for the delayed diagnosis. Multimodal imaging based on PET and MRI may assess the dynamics of disease onset and progression allowing the validation of preclinical models of glioblastoma multiforme (GBM). The aim of this study was...

Network

Cited By